Phase II trial of hul4.18-IL2 for patients with metastatic melanoma
Phase II trial of hul4.18-IL2 for patients with metastatic melanoma
About this item
Full title
Phase II trial of hul4.18-IL2 for patients with metastatic melanoma
Author / Creator
Journal title
Cancer immunology, immunotherapy : CII, 2012-06, Vol.61 (12), p.2261-2271
Language
English
Formats
More information
Scope and Contents
Contents
Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients (pts) showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m
2
/day. In this phase II study, fourteen pts with measurable metastatic melanoma were scheduled to receive hu14.18-IL2 at 6 mg/m
2
/day as 4-hour intravenous infusions on...
Alternative Titles
Full title
Phase II trial of hul4.18-IL2 for patients with metastatic melanoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3502633
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3502633
Other Identifiers
ISSN
0340-7004
E-ISSN
1432-0851
DOI
10.1007/s00262-012-1286-5
How to access this item
Log in as a Library member
